CorMedix Inc. (CRMD) income statement
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$4.50−0.17 (-3.64%)
Close on Nov 18, 2026Market cap $350.75MP/E –Yield –
CorMedix Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 82.8%
- Operating margin
- 47.0%
- Net margin
- 40.5%
- Return on equity, FY2025
- 66.6%
Financial strength
- Current ratio
- 2.56
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 137.0%
Valuation
- P/E ratio
- –
- Price to sales
- 0.76
- Price to book
- 0.76
- Dividend yield
- –
See a number that looks wrong?